中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.034 seconds)

    Inhibitors of Human EZH2, and Methods of Use Thereof
    23.
    发明申请
    Inhibitors of Human EZH2, and Methods of Use Thereof 有权
    人类EZH2抑制剂及其使用方法

    公开(公告)号：US20170065628A1

    公开(公告)日：2017-03-09

    申请号：US15132724

    申请日：2016-04-19

    Applicant: Epizyme, Inc.

    Inventor： Robert A. Copeland ,  Victoria M. Richon ,  Margaret D. Scott ,  Christopher J. Sneeringer ,  Kevin W. Kuntz ,  Sarah K. Knutson ,  Roy M. Pollock

    IPC: A61K31/7076

    CPC classification number: A61K31/7076 ,  C07D473/34 ,  C07D493/04 ,  C12Q1/48 ,  C12Q1/6876 ,  G01N33/5011 ,  G01N33/57426 ,  G01N2333/91011

    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Abstract translation: 本发明涉及抑制人组蛋白甲基转移酶EZH2的野生型和某些突变体形式，其是催化组蛋白H3（H3-K27）上赖氨酸27的单通三甲基化的PRC2复合物的催化亚单位。 在一个实施方案中，抑制对于EZH2的突变体形式是选择性的，使得与某些癌症相关的H3-K27的三甲基化被抑制。 该方法可用于治疗包括滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤（DLBCL）的癌症。 还提供了用于鉴定EZH2的突变形式的小分子选择性抑制剂的方法以及用于测定受试者中对EZH2抑制剂的反应性的方法。

    Inhibitors of Human EZH2, and Methods of Use Thereof
    24.
    发明申请
    Inhibitors of Human EZH2, and Methods of Use Thereof 有权
    人类EZH2抑制剂及其使用方法

    公开(公告)号：US20150141362A1

    公开(公告)日：2015-05-21

    申请号：US14540977

    申请日：2014-11-13

    Applicant: EPIZYME, INC.

    Inventor： Robert A. Copeland ,  Victoria M. Richon ,  Margaret D. Scott ,  Christopher J. Sneeringer ,  Kevin W. Kuntz ,  Sarah K. Knutson ,  Roy M. Pollock

    IPC: A61K31/7076

    CPC classification number: A61K31/7076 ,  C07D473/34 ,  C07D493/04 ,  C12Q1/48 ,  C12Q1/6876 ,  G01N33/5011 ,  G01N33/57426 ,  G01N2333/91011

    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Abstract translation: 本发明涉及抑制人组蛋白甲基转移酶EZH2的野生型和某些突变体形式，其是催化组蛋白H3（H3-K27）上赖氨酸27的单通三甲基化的PRC2复合物的催化亚单位。 在一个实施方案中，抑制对于EZH2的突变体形式是选择性的，使得与某些癌症相关的H3-K27的三甲基化被抑制。 该方法可用于治疗包括滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤（DLBCL）的癌症。 还提供了用于鉴定EZH2的突变形式的小分子选择性抑制剂的方法以及用于测定受试者中对EZH2抑制剂的反应性的方法。

    Inhibitors of human EZH2 and methods of use thereof
    25.
    发明授权
    Inhibitors of human EZH2 and methods of use thereof 有权
    人类EZH2抑制剂及其使用方法

    公开(公告)号：US08691507B2

    公开(公告)日：2014-04-08

    申请号：US13949026

    申请日：2013-07-23

    Applicant: Epizyme, Inc.

    Inventor： Robert A. Copeland ,  Victoria M. Richon ,  Margaret D. Scott ,  Christopher J. Sneeringer ,  Kevin W. Kuntz ,  Sarah K. Knutson ,  Roy M. Pollock

    IPC: C12Q1/68 ,  A61P35/00 ,  C07H21/00 ,  C07H21/04

    CPC classification number: A61K31/7076 ,  C07D473/34 ,  C07D493/04 ,  C12Q1/48 ,  C12Q1/6876 ,  G01N33/5011 ,  G01N33/57426 ,  G01N2333/91011

    Abstract: The invention relates to determining the presence of an EZH2 gene mutation in a sample from a subject and inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono-through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Abstract translation: 本发明涉及确定来自受试者的样品中EZH2基因突变的存在和抑制人组蛋白甲基转移酶EZH2的野生型和某些突变形式，其是催化单通三甲基化的PRC2复合物的催化亚单位 赖氨酸27在组蛋白H3（H3-K27）上。 在一个实施方案中，抑制对于EZH2的突变体形式是选择性的，使得与某些癌症相关的H3-K27的三甲基化被抑制。 该方法可用于治疗包括滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤（DLBCL）的癌症。 还提供了用于鉴定EZH2的突变形式的小分子选择性抑制剂的方法以及用于测定受试者中对EZH2抑制剂的反应性的方法。

Patent Agency Ranking